LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

LLY

999.26

-0.72%↓

JNJ

228.04

-0.74%↓

ABBV

209.97

-0.24%↓

UNH

391

-2.31%↓

AZN

181.67

-1.91%↓

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Atidarymo kaina

10.13 -1.27

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.93

Max

10.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-154M -183M
Pelnas, tenkantis vienai akcijai	-0.6
Darbuotojai	103
EBITDA	-156M -188M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+93.79% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-18

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.6B 3.2B
Ankstesnė atidarymo kaina	11.4
Ankstesnė uždarymo kaina	10.13

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-14 22:44; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026-05-14 22:27; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026-05-14 22:12; UTC

Uždarbis

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026-05-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs

2026-05-15 00:00; UTC

Uždarbis

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026-05-14 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026-05-14 23:56; UTC

Rinkos pokalbiai

Gold Prices Rise on Strong Demand -- Market Talk

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026-05-14 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026-05-14 23:47; UTC

Uždarbis

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026-05-14 23:47; UTC

Uždarbis

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026-05-14 23:28; UTC

Rinkos pokalbiai

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026-05-14 23:00; UTC

Rinkos pokalbiai

Australia's One Nation Party Leads In The Polls -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-14 22:35; UTC

Rinkos pokalbiai

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026-05-14 22:11; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026-05-14 22:06; UTC

Rinkos pokalbiai

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026-05-14 22:00; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q EPS 18c >NU

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q Rev $4.97B >NU

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

93.79% į viršų

12 mėnesių prognozė

Vidutinis 20.27 USD 93.79%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.